Study power is the holy grail of clinical trials, setting drug developers on the quickest path to market — but nonadherence causes costly detours. When participants do not take their medication as specified in the study protocol, it can result in underestimated drug efficacy, delay the approval of investigational products, and contribute to rising costs.…